Seasonal Affective Disorder Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Seasonal Affective Disorder Therapeutics market is segmented by Drug Type (Selective Serotonin Reuptake Inhibitors, Norepinephrine-Dopamine Reuptake Inhibitor, Monoamine Oxidase Inhibitor, Others), Disorder Type (Unipolar Disorder, Bipolar Disorder), Distribution Channel (Institutional Sales, Retail Sales), and Geography

Market Snapshot

Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 6.3 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Seasonal Affective Disorder Therapeutics market studied is anticipated to grow with a CAGR of nearly 6.3%, during the forecast period.

  • Certain factors that are driving the market growth include increasing prevalence of seasonal affective disorder and depression, growing R&D activities, and the rising number of treatment options.
  • Various antipsychotic medications are currently being used as a short-term treatment for bipolar disorder to control psychotic symptoms, such as hallucinations, delusions, or mania symptoms. These symptoms may occur during acute mania or severe depression. Some also treat bipolar depression, and several have demonstrated long-term value in preventing future episodes of mania or depression.
  • In people with bipolar disorder, antipsychotics are also used "off label" as sedatives, for insomnia, for anxiety, and/or for agitation. Often, they are taken with a mood-stabilizing drug and can decrease the symptoms of mania until mood stabilizers take full effect. Some medications seem to help stabilize moods on their own. The growing R&D activities are expected to fuel the market growth over the forecast period.

Scope of the Report

As per the scope of the report, seasonal affective disorder refers to a mood disorder characterised by depression that occurs at the same time every year. Seasonal affective disorder occurs in climates where there is less sunlight at certain times of the year. Symptoms include fatigue, depression, hopelessness and social withdrawal. The report covers the different types of drugs used to treat these disorders.

By Drug Type
Selective Serotonin Reuptake Inhibitors (SSRI)
Norepinephrine-Dopamine Reuptake Inhibitor (NDRI)
Monoamine Oxidase Inhibitor (MAOI)
By Disorder Type
Unipolar Disorder
Bipolar Disorder
By Distribution Channel
Institutional Sales
Retail Sales
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Bipolar Disorder Holds Significant Share in the Seasonal Affective Disorder Therapeutics Market

There is an increasing prevalence of bipolar disorder owing to the various risk factors, such as high stress, substance abuse, and others. According to the estimates of the Institute for Health Metrics and Evaluation (IHME), Global Burden of Diseases, the prevalence of bipolar disorder across the world varies from 0.3 to 1.2% by country. In 2017 around 46 million people in the world had bipolar disorder, with 52% and 48% being female and male, respectively. The typical age of onset is the late teens or the early 20s, and a history of depression is common in people diagnosed with bipolar. The probability of men and women are being affected by bipolar disorder is similar. Hence, the rise in the cases of the disease and the increasing need to manage them effectively has led to the growth of the seasonal affective disorder therapeutics market.

seg sadt.PNG

North America Dominates the Seasonal Affective Disorder Therapeutics Market

North America is found to hold a major share for the seasonal affective disorder therapeutics market and is expected to show a similar trend over the forecast period, without significant fluctuations. Due to the increasing cases of bipolar disorder and the presence of better healthcare infrastructure, the market is expected to witness high growth over the forecast period.

According to the data published by the National Alliance on Mental Illness, around 1 in 5 adults in the United States experiences mental illness each year. Hospitalization is required for severe episodes of mania and depression to protect the patients from injuring themselves or others. According to the NIMH, bipolar disorder is characterized in part by manic symptoms that are so severe that the person needs immediate hospital care. There is a huge need to tackle mental disorder, as it is an increasing problem, and hence, the market is expected to grow during the forecast period.

geo sadt.png

Competitive Landscape

The global Seasonal Affective Disorder Therapeutics market is competitive and consists of a few major players. Companies like AbbVie Inc., Eli Lilly and Company, F. Hoffman-La Roche AG, GlaxoSmithKline plc., Mylan N.V., Novartis AG, Pfizer Inc., Teva Pharmaceuticals USA, Inc., among others, hold the substantial market share in the market.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Seasonal Affective Disorder and Depression

      2. 4.2.2 Growing R&D Activities and Rising Number of Treatment Options

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Awareness across Regions

      2. 4.3.2 Probable Side Effects and Risks

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Drug Type

      1. 5.1.1 Selective Serotonin Reuptake Inhibitors (SSRI)

      2. 5.1.2 Norepinephrine-Dopamine Reuptake Inhibitor (NDRI)

      3. 5.1.3 Monoamine Oxidase Inhibitor (MAOI)

      4. 5.1.4 Others

    2. 5.2 By Disorder Type

      1. 5.2.1 Unipolar Disorder

      2. 5.2.2 Bipolar Disorder

    3. 5.3 By Distribution Channel

      1. 5.3.1 Institutional Sales

      2. 5.3.2 Retail Sales

    4. 5.4 Geography

      1. 5.4.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.4.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 AbbVie Inc.

      2. 6.1.2 Eli Lilly and Company

      3. 6.1.3 F. Hoffman-La Roche AG

      4. 6.1.4 GlaxoSmithKline plc.

      5. 6.1.5 Mylan N.V.

      6. 6.1.6 Novartis AG

      7. 6.1.7 Pfizer Inc.

      8. 6.1.8 Teva Pharmaceuticals USA, Inc.

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Seasonal Affective Disorder Therapeutics Market market is studied from 2018 - 2026.

The Seasonal Affective Disorder Therapeutics Market is growing at a CAGR of 6.3% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

AbbVie Inc. , Eli Lilly and Company , GlaxoSmithKline plc. , Teva Pharmaceuticals USA, Inc. , Pfizer Inc. are the major companies operating in Seasonal Affective Disorder Therapeutics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!